Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., Dauba, J., Dupuis, O., Rinaldi, Y., Mabro, M., Aucoin, N., Latreille, J., Bonnetain, F., Louvet, C., Larsen, A. K., André, T., & de Gramont, A. (2015). bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet oncology, 16(15), 1493–1505. http://access.bl.uk/ark:/81055/vdc_100029140639.0x00000e